BLOG

FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

Acepodia’s off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}